Drug Delivery Device for Age-Related Macular Degeneration (AMD)
Karl G. Csaky, M.D., Ph.D., Director, Molecular Ophthalmology Laboratory, is working with his research team to develop a drug delivery device for patients with age-related macular degeneration (AMD). It is a small Polymer device that slowly releases therapeutic drugs as needed over a period of weeks, months or years as prescribed by your physician. The device is placed on the outer part of the eye and does not interfere with patient vision or comfort. The device can remain in place for a long period of time as prescribed by the physician care team. Placement of the implant on the surface of the eye, rather than inside the eye, allows for long-term drug delivery to the eye. This innovative drug delivery device allows physicians to administer medication delivery in a less invasive way, and better manage the disease.
Related ArticlesPhase III Treatment Trial for Stargardt Disease Enrolls First Patient Anonymous One Million Dollar Gift Given to Retina Foundation for AMD Research Retina Foundation to Conduct First Optogenetics Gene Therapy Clinical Trial Children With Amblyopia and Strabismus Take Longer To Complete Answer Forms iPad App for Detecting Retinal Disease Receives Second FDA Approval